Biogen Idec Signs Third Antisense Deal of 2012 with Isis Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 12 (Table of Contents)
Published: 31 Dec-2012
DOI: 10.3833/pdr.v2012.i12.1865 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Biogen Idec and Isis Pharmaceuticals are joining forces for a third time with a global collaboration to discover and develop antisense drug candidates against three undisclosed targets to treat neurological or neuromuscular disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS